{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:49:02Z","timestamp":1785944942431,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Despite the absence of adequate safety or efficacy data, clindamycin is widely prescribed in the neonatal intensive care unit. We evaluated the association between clindamycin exposure and adverse events, as well as antibiotic effectiveness in infants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a retrospective cohort study of infants receiving clindamycin before postnatal day 121 who were discharged from a Pediatrix Medical Group neonatal intensive care unit (1997\u20132015). Using a previously developed pharmacokinetic model, we performed simulations to predict clindamycin exposure based on available dosing data. We used multivariable logistic regression to evaluate the association between clindamycin exposure and safety outcomes during and after clindamycin therapy. We reported the proportion of infants with methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> (MRSA) bacteremia and clearance of MRSA bacteremia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 4089 infants received clindamycin at a median (25th\u201375th percentile) dose of 15\u2009mg\/kg\/d (12\u201316). Clearance increased with older gestational age. Infants with the highest total clindamycin exposure had marginally increased odds of necrotizing enterocolitis within 7 days (adjusted odds ratio = 1.95 [1.04\u20133.63]), but exposure was not associated with death, sepsis, seizures, intestinal perforation or intestinal strictures. Of 25 infants who had MRSA bacteremia, 19 (76%) cleared the infection by the end of the clindamycin course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Higher clindamycin exposure was not associated with increased odds of death or nonlaboratory adverse events. The use of pharmacokinetic models combined with available electronic health record data offers a valuable, cost-effective approach to analyzing the safety and effectiveness of drugs in infants when large-scale trials are not feasible.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002524","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T19:29:37Z","timestamp":1573673377000},"page":"204-210","source":"Crossref","is-referenced-by-count":9,"title":["A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants"],"prefix":"10.1097","volume":"39","author":[{"given":"Rachel G.","family":"Greenberg","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Maharaj","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay M.","family":"Tomashek","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire L.","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reese H.","family":"Clark","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"},{"name":"Pediatrix Medical Group, Sunrise, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit.","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am J Perinatol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-3468(80)80775-5","article-title":"The microbial flora and antimicrobial therapy of neonatal peritonitis.","volume":"15","author":"Bell","year":"1980","journal-title":"J Pediatr Surg"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1542\/peds.2011-0966","article-title":"Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants.","volume":"129","author":"Shane","year":"2012","journal-title":"Pediatrics"},{"key":"R6-20230912","first-page":"287","article-title":"Pharmacokinetics of intravenous clindamycin in newborn infants.","volume":"5","author":"Koren","year":"1986","journal-title":"Pediatr Pharmacol (New York)"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.03086-15","article-title":"Clindamycin pharmacokinetics and safety in preterm and term infants.","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/clpt.2014.134","article-title":"Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.","volume":"96","author":"Gonzalez","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpeds.2011.02.035","article-title":"Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis.","volume":"159","author":"Alexander","year":"2011","journal-title":"J Pediatr"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(88)80069-6","article-title":"A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis.","volume":"112","author":"Faix","year":"1988","journal-title":"J Pediatr"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clp.2010.01.016","article-title":"The pediatrix babySteps data warehouse and the pediatrix qualitySteps improvement project system\u2013tools for \u201cmeaningful use\u201d in continuous quality improvement.","volume":"37","author":"Spitzer","year":"2010","journal-title":"Clin Perinatol"},{"key":"R14-20230912","first-page":"137","article-title":"A multifaceted approach to improving outcomes in the NICU: the pediatrix 100\u2009000 babies campaign.","author":"Ellsury","year":"2016","journal-title":"Pediatrics"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1542\/peds.2011-3028","article-title":"Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009.","volume":"129","author":"Horbar","year":"2012","journal-title":"Pediatrics"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2015.10244","article-title":"Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012.","volume":"314","author":"Stoll","year":"2015","journal-title":"JAMA"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15585\/mmwr.mm6531a2","article-title":"Incidence of neonatal abstinence syndrome - 28 states, 1999-2013.","volume":"65","author":"Ko","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs.","volume":"372","author":"Tolia","year":"2015","journal-title":"N Engl J Med"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0031-3955(16)34975-6","article-title":"Necrotizing enterocolitis: treatment based on staging criteria.","volume":"33","author":"Walsh","year":"1986","journal-title":"Pediatr Clin North Am"},{"issue":"suppl 2","key":"R20-20230912","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0378-3782(12)70019-1","article-title":"Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units.","volume":"88","author":"Hornik","year":"2012","journal-title":"Early Hum Dev"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1542\/peds.2009-0913","article-title":"New intrauterine growth curves based on United States data.","volume":"125","author":"Olsen","year":"2010","journal-title":"Pediatrics"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.pcl.2012.07.007","article-title":"Ethical issues in neonatal and pediatric clinical trials.","volume":"59","author":"Laventhal","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.2009.207","article-title":"Clinical trials in neonates: a therapeutic imperative.","volume":"86","author":"Ward","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/INF.0000000000001610","article-title":"Use of population pharmacokinetics and electronic health records to assess piperacillin-tazobactam safety in infants.","volume":"36","author":"Salerno","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpeds.2016.07.011","article-title":"Electronic health records and pharmacokinetic modeling to assess the relationship between ampicillin exposure and seizure risk in neonates.","volume":"178","author":"Hornik","year":"2016","journal-title":"J Pediatr"},{"key":"R27-20230912","first-page":"62","article-title":"External evaluation of a gentamicin infant population pharmacokinetic model using data from a national electronic health record database.","author":"Ge","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01046-07","article-title":"Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.","volume":"52","author":"LaPlante","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.43.8.2005","article-title":"Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.","volume":"43","author":"Lewis","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/00007611-197707000-00018","article-title":"Endocarditis treated with clindamycin: relapse and liver dysfunction.","volume":"70","author":"Hinthorn","year":"1977","journal-title":"South Med J"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0002-9343(74)90015-1","article-title":"Clindamycin-associated hepatotoxicity.","volume":"57","author":"Elmore","year":"1974","journal-title":"Am J Med"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/cpt1972135part1704","article-title":"Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection.","volume":"13","author":"Kauffman","year":"1972","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 4","key":"R34-20230912","first-page":"22","article-title":"Haematological abnormalities in neonatal necrotizing enterocolitis.","volume":"25","author":"Song","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6 Pt 1","key":"R35-20230912","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1542\/peds.111.6.1411","article-title":"Platelet count and sepsis in very low birth weight neonates: is there an organism-specific response?","volume":"111","author":"Guida","year":"2003","journal-title":"Pediatrics"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.inf.0000073163.37519.ee","article-title":"Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children.","volume":"22","author":"Mart\u00ednez-Aguilar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R37-20230912","first-page":"508","article-title":"Community-acquired Staphylococcus aureus bacteremia in children: a cohort study for 2010-2014.","volume":"114","author":"P\u00e9rez","year":"2016","journal-title":"Arch Argent Pediatr"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1365-2885.1998.00111.x","article-title":"Contribution of alpha 1-acid glycoprotein to species difference in lincosamides-plasma protein binding kinetics.","volume":"21","author":"Son","year":"1998","journal-title":"J Vet Pharmacol Ther"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1128\/AAC.42.9.2427","article-title":"Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.","volume":"42","author":"Zhanel","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.40.5.1134","article-title":"Protein binding of clindamycin in sera of patients with AIDS.","volume":"40","author":"Flaherty","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1208\/ps040104","article-title":"Protein binding predictions in infants.","volume":"4","author":"McNamara","year":"2002","journal-title":"AAPS PharmSci"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/adc.61.7.657","article-title":"Serum albumin concentrations and oedema in the newborn.","volume":"61","author":"Cartlidge","year":"1986","journal-title":"Arch Dis Child"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:16:18Z","timestamp":1694556978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002524","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}